

Linezolid en neumonía. Pros y contras

Moderador: José M^a Gutiérrez Urbón
Servicio de Farmacia
Complejo Hospitalario Universitario A Coruña

Neumonía adquirida en la comunidad

Microorganismos

Streptococcus pneumoniae

Haemophilus influenzae

Legionella pneumophila

Mycoplasma pneumoniae

Chlamydia pneumoniae

Tratamiento

Betalactámico antineumococo

Macrólido

Fluoroquinolona 3-4^a generación

Neumonía nosocomial

Microorganismos

Pseudomonas aeruginosa

Staphylococcus aureus meticilin-resistente

Tratamiento

**Betalactámico anti-pseudomonas
± aminoglucósido // quinolonas**

+

Agente anti-SARM

Agentes anti-SARM

~~Vancomicina/teicoplanina~~

~~Quinupristina/dalfopristina~~

Linezolid

~~Tigeciclina~~

~~Daptomicina~~



NEUMONÍA

Distribución al pulmón





FIG. 2. Mean concentrations of linezolid in eELF. SDs and the range for each time period are given in Table 2. The MIC₉₀s for *S. aureus*, *Enterococcus spp.*, and *S. pneumoniae* are included for comparison.


Eficacia clínica

- Rubinstein E, et al. Linezolid versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: A randomized, double-blind, multicenter study. Clin Infect Dis 2001; 32:402-12.
- Wunderink RG, et al. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther 2003; 25:980-92.

- **Análisis retrospectivo conjunto en subgrupo con SARM:**

LIN > VANCO  **respuesta clínica**
supervivencia

Vancomicina y CMI SARM



Arch Intern Med 2006; 166:2138-44
Clin Infect Dis 2004; 38(12):1700-5
J Clin Microbiol 2004; 42(6): 2398-2402

Metaanálisis

Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: a systematic review and meta-analysis.

LIN no superior clínicamente a VANCO

LIN  **+ trombocitopenia**
+ RA gastrointestinales

VANCO  **no + nefrotoxicidad**

Cara a cara NN por SARM


Linezolid vs vancomycin in the treatment of nosocomial pneumonia proven due to methicillin-resistant *Staphylococcus aureus*

Kunkel M, et al. Abstract LB-49

48th Infectious Disease Society of America,
Annual Meeting October 23, 2010.

Vancouver, BC, Canadá.

Linezolid en neumonía. Pros y contras



Luis Álvarez Rocha
Unidad de Cuidados Intensivos
Complejo Hospitalario Universitario A Coruña